Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors

NCT03423628 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03423628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03423628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 2, 2018
Completion date
September 3, 2026
Enrollment
159 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, malignant, leptomeningeal disease (lmd), primary glioblastoma multiforme, recurrent glioblastoma multiforme